Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25329259 | 1.00 | FABP7 (0.38) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL25327878 | 0.96 | FABP7 (0.37) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL25327880 | 0.96 | FABP7 (0.37) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL30523039 | 0.95 | TACR1 (0.37) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL25328181 | 0.95 | TACR1 (0.37) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL30522989 | 0.91 | TACR1 (0.38) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL25325851 | 0.91 | TACR1 (0.38) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL25327418 | 0.91 | FABP7 (0.32) | FABP7RIPK1TACR1PDK1PDK2 | |
| SCHEMBL25327836 | 0.87 | PSEN1 (0.32) | FABP7RIPK1TACR1SCN9A | |
| SCHEMBL25325665 | 0.86 | FABP7 (0.40) | FABP7RIPK1TACR1PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | FABP7 4876/4885RIPK1 4782/4885TACR1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.